Issue and repurchase of series C shares for performance-based share saving program
Pursuant to the authorization granted by the annual general meeting on 1 June 2021, the board of directors of Alligator Bioscience AB (”Alli ...
The Nomination Committee’s proposal regarding the Board of Directors ahead of the Annual General Meeting 2022 in Alligator Bioscience AB
REGULATORY 11 March 2022 Ahead of the Annual General Meeting in Alligator Bioscience AB on May 5, 2022, the Nomination Committee announces i ...
Alligator Bioscience AB: Interim report January–September 2021
First Patient Dosed in Optimize-1 Phase II “We continued to make great strides in the third quarter of 2021. The first patient was dosed in ...
Alligator Bioscience AB: Interim report January–March 2021
High activity during the first quarter ”So far, 2021 has been characterized by high activity, with a research collaboration that validates o ...
Alligator Bioscience publishes Annual Report for 2020
Lund, Sweden, March 18, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2020 has been publi ...
Alligator Bioscience AB: Year-end Report January-December 2020
Continued focus on clinical development. “Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with meta ...
Alligator Bioscience AB (publ): Interim report January-September 2020
Encouraging clinical safety data for ATOR-1017 The Phase I study with ATOR-1017 has progressed exceptionally well and in August we presented ...
Alligator Bioscience AB (publ) Interim report January-June 2020
Promising safety data for ATOR-1015 "With the new strategy announced in early April, we have put a stronger focus on Alligator’s clinica ...
Alligator Bioscience’s Annual Report 2019 published
Lund, Sweden, 2 March 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutica ...